EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study

Martins-Branco D, Lobo-Martins S, Aftimos P, Pereira B, Vasconcelos de Matos L, Fernandes L, Campôa E, Nader-Marta G, Moreau M, Taylor D, Duhoux FP, …, de Azambuja E · 2026 · Breast Cancer Research and Treatment · Atlas ID MAR2026

What this study shows

Everolimus added to endocrine therapy provided modest but statistically significant PFS benefit (5.0 vs 4.3 months; HR 0.68) in ER+/HER2- advanced breast cancer post-CDK4/6 inhibitor progression, without demonstrable OS benefit, supporting selective use. Retrospective and non-randomised, so treatment-selection bias cannot be excluded.

Abstract

ShowHide

Multicentre, international, retrospective quasi-experimental study (n=207 women with ER+/HER2- advanced breast cancer after CDK4/6 inhibitor progression). Everolimus + endocrine therapy (n=150) vs endocrine therapy alone (n=57). Median real-world PFS: 5.0 vs 4.3 months (adjusted HR 0.68, 95% CI 0.47-0.99). Time to everolimus failure: 4.2 months. No significant differences in time to chemotherapy or overall survival. Safety profile consistent with prior reports. Median follow-up 31.8 months.

Read the full abstract on PubMed →

At a glance

Evidence type	H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H.
Study type	3 - Human Observational
Model system	Human (multicenter retrospective cohort)
Journal	Breast Cancer Research and Treatment
Year	2026
Peer reviewed	Yes
Record last updated	2026-07-29
Source	DOI 10.1007/s10549-026-08012-5 · PMID 42429895

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	Everolimus (mTOR inhibitor) + endocrine therapy
Target	mTORC1
Model	Human
Effect	Modest PFS improvement (HR 0.68) in post-CDK4/6i ER+ breast cancer; no OS benefit demonstrated

In the Atlas

Cite this paper

ShowHide

Martins-Branco, D., Lobo-Martins, S., Aftimos, P., Pereira, B., Vasconcelos de Matos, L., Fernandes, L., Campôa, E., Nader-Marta, G., Moreau, M., Taylor, D., Duhoux, F. P., Simões, P., Garcia, A. R., Patel, V., Confente, C., Alpuim Costa, D., Pereira, J., Santos, C., Paesmans, M., Sarmento, F., Gantes Padrão, T., Simão, D., Bandarra, D., Sousa, B., Brito, M., Gombos, A., Ameye, L., & de Azambuja, E. (2026). EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08012-5

@article{MAR2026,
  author       = {Martins-Branco, D. and Lobo-Martins, S. and Aftimos, P. and Pereira, B. and Vasconcelos de Matos, L. and Fernandes, L. and Campôa, E. and Nader-Marta, G. and Moreau, M. and Taylor, D. and Duhoux, F. P. and Simões, P. and Garcia, A. R. and Patel, V. and Confente, C. and Alpuim Costa, D. and Pereira, J. and Santos, C. and Paesmans, M. and Sarmento, F. and Gantes Padrão, T. and Simão, D. and Bandarra, D. and Sousa, B. and Brito, M. and Gombos, A. and Ameye, L. and de Azambuja, E.},
  title        = {{EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study}},
  journal      = {Breast Cancer Research and Treatment},
  year         = {2026},
  doi          = {10.1007/s10549-026-08012-5},
  note         = {PMID: 42429895},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record MAR2026) [Data set]. https://mtor-atlas.org/study/MAR2026/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_MAR2026,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record MAR2026},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/MAR2026/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?